Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) just unveiled an announcement.
QIAGEN has disclosed that the Dutch financial regulator AFM notified the company of a substantial shareholding and related financial instruments held by Goldman Sachs Group Inc. as of January 28, 2026. Through a mix of ordinary shares, convertible bonds, swaps, warrants and options held via multiple Goldman Sachs entities, the U.S. bank controls a combined capital and voting interest of 3.11% in QIAGEN, underscoring ongoing institutional investor engagement in the stock and potentially influencing liquidity and market perception of the company’s shareholder structure.
The most recent analyst rating on (QGEN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and molecular diagnostics company whose shares are listed on several European exchanges as well as the NYSE and Swiss venues, giving it broad access to international capital markets.
Average Trading Volume: 1,843,471
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.1B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.